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Abstract
Background: Diseases of the digestive system have been found to contribute to a higher symptom burden in
older adults. Thus, therapeutic strategies able to treat gastrointestinal discomfort might impact the overall health
status and help older adults to increase their overall health status and optimal functionality.
Objective: The aim of this double-blinded, randomized, placebo-controlled clinical trial was to evaluate the effect
of the probiotic strain Lactobacillus reuteri on digestive health and wellbeing in older adults.
Methods: The study enrolled general older adults (>65 years). After eligibility screening qualified subjects (n = 290)
participated in a 2-arm study design, with each arm consisting of 12 weeks of intervention of either active or placebo
product. Primary outcome measure was set to changes in gastrointestinal symptoms and secondary outcome
measures were changes in level of wellbeing, anxiety and stress. Follow up was performed at 8 and 12 weeks.
Results: No persistent significant effects were observed on the primary or secondary outcome parameters of the study.
A modest effect was observed in the probiotic arm, were levels of stress decreased at week 8 and 12. Similarly, we
found that subjects suffering from indigestion and abdominal pain, respectively, showed a significant decrease of
anxiety at week 8 after probiotic treatment, but not at week 12.
Conclusion: The RCT failed to show any improvement in digestive health after daily intake of a probiotic supplement
containing L. reuteri. Neither was any significant improvement in wellbeing, stress or anxiety observed. Even though the
RCT had a negative outcome, the study highlights issues important to take into consideration when designing trials
among older adults.
Trial registration: Clinicaltrials.gov/NCT01837940.
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Introduction
The aging process is characterized by loss of function;
particularly cognitive functions, as well as gastrointes-
tinal problems are widespread phenomena among older
adults. Diseases of the digestive system have been found
to contribute to a higher symptom burden in a popula-
tion of Swedish free-living older adults [1]. Acute and
chronic diarrhea is frequently observed often resulting
in an aberrant stool pattern restricting the older adults’
everyday life [1, 2]. A well functioning gastrointestinal
tract is essential for older adults to experience life-
satisfaction and meaningfulness [3, 4]. Today, little is
known about the mechanisms behind age-associated gut
problems and few treatment options designed only for
older adults exist. Hence, therapeutic strategies able to
treat gastrointestinal discomfort might impact the overall
health status and personal integrity among the oldest old.
The diversity of the gut microbiota has been identified
as a major contributor to gut health and is known to in-
fluence the intestinal barrier function (e.g. the capacity
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of the intestine to act as a wall against bacterial products
and food antigens and yet being able to take up nutrients),
as well as being vital for a well-functioning immune sys-
tem [5, 6]. Moreover, the gut microbiota has recently been
identified as an important player in the gut-brain axis,
linking emotional and cognitive centers of the brain
with peripheral intestinal functions [7]. Therapies able
to beneficially affect the gut microbiota composition, such
as probiotic bacteria (e.g. live bacterial strains expressing
beneficial health effects on the host), might alleviate
gastrointestinal discomfort and increase overall health
status among older adults.
The probiotic species L. reuteri is an endogenous
organism [8, 9] able to modulate the gut microbiota
through the production of reuterin, a potent antibacterial
compound, capable of inhibiting a wide spectrum of
microorganisms [10]. L. reuteri has been identified as
a promising therapy in various gastrointestinal disorders
[11–13], including functional chronic constipation [14, 15].
Here, we aim to conduct a double-blinded, randomized,
placebo-controlled study with the aim to investigate digest-
ive health after the intake of a dietary supplement, consist-
ing of the probiotic strain L. reuteri, during a three-month
period. Furthermore, we evaluated whether a change in di-
gestive health correlated to an improved subjective percep-




The study population was recruited through advertise-
ments in local and regional newspapers. At senior living
homes information meetings were held and flyers were
handed out to all residents. The study population was
recruited from the region of Örebro, within a 45 km
radius from the City center. Residents at the senior liv-
ing homes were invited to participate after careful
presentation of the protocol, individual discussion if
needed, and signing of the consent form. A total popu-
lation of 307 eligible free-living older adults (mean age
73.1, range 65-98) was recruited between January and
March 2013. All participants lived in their own home.
Each study participant was assigned a contact person
(a medical student informed in detail about the study
procedures).
Inclusion and exclusion criteria
Each older adult had to meet the following criteria to be
enrolled in the study:
 Informed consent signed by study participant
 Age ≥65 years
 Mentally and physically fit to complete
questionnaires during the study period.
Older adults meeting any of the following criteria were
excluded from the study:
 Any known gastrointestinal disease, with strictures,
malignance’s and ischemia.
 Inflammatory bowel diseases
 Participation in other clinical trials in the past three
months.
Study design
This study was a double-blinded, randomized, placebo-
controlled clinical trial enrolling free-living older adults
(≥65 years) representing the general population in the re-
gion of Örebro, Sweden. The treatment period was
12 weeks and the intervention parameters were evaluated
at week 0, 8 and 12. All subjects entered the intervention
phase within two weeks. Two weeks prior follow up a re-
minder was sent by mail to all participants with a sugges-
tion of day and time to meet or phone their contact
person (assigned at enrolment). The participants were
asked to confirm the time one-week prior follow up.
Three phone calls were placed on three consecutive days
to participants not responding to the letter. As a final step
a home visit was made on the day assigned for follow up.
The contact person assisted the study participant to assure
that the questionnaires were answered correctly. A
study diary was provided to all participants were the
daily stool frequency was monitored and new medica-
tions were reported. The active study product consisted
of a stick-pack containing freeze-dried L. reuteri DSM
17938 (1 × 108 colony forming units/stick-pack), rham-
nose, galactooligosaccharide and maltodextrin to a total
weight of 1 g. The placebo product consisted of maltodex-
trin with the same appearance, color and taste as the active
study product, identically packaged and stored. The study
product was packed and labeled by BioGaia AB. Active and
placebo stick-packs were packed identically with the num-
ber of the subject and storing instructions. All products
were blinded and randomized by BioGaia AB. For the re-
search team, a blinded randomization list was provided
with the subject sequence and subject number. The re-
search team allocated the study participants by randomly
assigning the pre-labeled study product to the participants
and a screening record in which all screened subjects were
registered. For each subject enrolled, date of enrolment
and ID number of the trial subject was recorded. The iden-
tity of the specific product was blinded to all subjects, con-
tact persons and investigators. The coding was only known
to the representative of the BioGaia AB responsible for
product randomization and had no other involvement in
the trial. All other personnel at Bio Gaia AB involved in
the study as well as the research team and study staff
remained blinded to the study treatment until completion
of the statistical analysis and discussion of the findings.
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A statistical power calculation was performed on GSRS
data from the first 100 participants indicating that 74.2 %
of older adults suffer from gastrointestinal discomfort
(judged by a score of >2 at any domain of GSRS). A sam-
ple size of 150 per group (300 in total) provided 80 %
power with 95 % confidence interval to detect a minimum
clinical improvement in gastrointestinal discomfort of
20 % among the intervention arm and 5 % of the placebo
arm. Based on these calculations a decision was made to
aim to include at least 200 subjects in each group, 400 in
total, to assure that the study was adequately powered. In
total 307 study participants were recruited of these 290
were enrolled and randomized (Fig. 2). The study partici-
pants were instructed to take two stick-packs per day, at
breakfast or lunch, for a 12 week-period and to maintain
their normal dietary habits during the study-period.
Data collection
Demographic data
The following demographic information was collected in
order to better define the study population: age, sex,
education level, marital status, retirement age and smok-
ing habits (Table 1).
Medications
All prescribed medications taken during the 6 months
preceding the study start was assessed by self-reporting
by each recruited subject. Current prescription of medi-
cations was documented in the study CRF. The distribu-
tion of prescribed medications is shown in Table 1.
Intervention parameters
Gastrointestinal symptoms rating scale (GSRS)
Is a validated instrument, [16–18] previously used to assess
gastrointestinal discomfort among older adults [19]. The
scale measures 15 symptoms, which are divided into
5 domains (i.e. reflux, abdominal pain, indigestion, diar-
rhea and constipation). The total GSRS score was used, as
an estimate of the overall gastrointestinal discomfort.
Hospital anxiety and depression scale (HADS)
Is a widely used validated instrument for the evaluation of
psychological distress in medical settings as well as in
older adults [20, 21]. The instrument consists of 14 items,
consisting of two subscales for assessment of anxiety or
depression. The total score is used as a measure of
psychological distress.
EQ-5D-5L (EQ-5D index and EQ-VAS)
EuroQol is a standardized measure of health status [22]
and has been validated in older adults [23]. The tool
consists of two parts; 5Q-5D, which includes 5 items
related to wellbeing and function (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
and the visual analogue scale, 5Q-5D-VAS, ranging
from 0 to 100.
Perceived stress scale (PSS)
The instrument assess the perception of stress and has
been validated among older adults [24, 25]. The scale
consists of 10 items, including a number of direct quer-
ies about current levels of experienced stress. The re-
spondent answers how often a certain emotion has been
present during the past month. A total score was used
to illustrate the study participants’ perception of stress.
Daily stool frequency
The number of stools per day was monitored in the
study diary.
Monitoring of compliance and adverse events
Adherence was measured through a study diary that was
completed daily and where all study participants marked






Female % 57 65.6
Male % 43 34.4

















Non-Steroidal Anti-Inflammatory Substances 5 6.6
Blood Pressure Lowering Substances 32.8 27.9
Proton Pump Inhibitors 16.5 11.5
Opiates 3.3 1.6
Over-the-counter drugs %
GI Motility Modulating Substances 12.9 15.5
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if they taken the supplement at breakfast or at lunch.
Participants overlooking to take the supplement one day
per week (12 non-continuous days) or during four con-
secutive days throughout the study were considered
non-compliant, as taking the supplement sporadically
could affect the primary outcome. All adverse events
occurring after any administration of the study product
was followed until the end of the study. All adverse events
are shown in Fig. 1. No serious adverse events (e.g. events
resulting in death, immediately life-threatening, requiring
or prolonging hospitalization or resulting in persistent




As a first step all data was included in an intention-to-
treat (ITT) analysis. In a next step we performed a per-
protocol analysis. A responder was considered a subject
compliant to the protocol and experiencing a relief in
symptoms by a score of 0.5 (the minimal clinical rele-
vant change) on the mean value of GSRS or on any of
the domains. Gastrointestinal motility modulating sub-
stances (GMMS) and proton pump inhibitors (PPI) were
considered to affect this end point analysis. Hence, study
subjects taken these medications were excluded from
further analysis (n = 71). All substances excluded were
classified according to the Swedish environmental classifi-
cation of pharmaceuticals at www.fass.se. As a next step
the median (+ IQR) and mean (± SD) score of the GSRS
questionnaire for all subjects, including non-compliant
participants (n = 178), were calculated for week 8 and 12,
and are shown as changes from baseline in the results sec-
tion. Gastrointestinal problems at baseline were defined as
a score of >2 at any domain of GSRS, including mild to se-
vere problems. Separate GSRS domain scores for 8 and
for 12 weeks were tested for differences between the study
arms using a student’s t-test or Mann-Whitney U-test,
(Table 2). Sub analyses were performed in order to identify
if participants experiencing gastrointestinal symptoms, de-
fined as a score <2 on any domain of GSRS, experienced
any relief in anxiety, depression, stress or wellbeing after
probiotic supplement. Eighteen questionnaire items
(GSRS) had to be imputed due to missing data. The miss-
ing value was replaced with the arithmetic mean of the
completed items in the questionnaire, in accordance with
the instructions for the questionnaire.
Secondary outcome measures
The analyses of the secondary outcome parameters were
performed similar to the primary outcome parameters.
Initially, an ITT was performed followed by a per-protocol
analysis including a responder analysis of the compliant
subjects. As for the primary outcome no significant results
Assessed for eligibility (n=307) 
Excluded for not meeting the inclusion criteria (n=4) 
Randomized (n=290) 
Allocated to probiotics  (n=143)   
Received allocated treatment (n=140) 
Allocated to placebo  (n=147)   
Received allocated treatment (n=146) 
Lost to follow-up (n=11)   
Discontinued intervention (n=11) due to: 
Feeling constipated (n=3) 
Diarrhoea (n=1) 
Abdominal pain (n=1) 
Undefined GI problems (n=1) 
Urinary tract infection (n=1) 
Inguinal hernia (n=1) 
No reason given (n=2) 
8 week follow-up 
Lost to follow-up (n=20)   
Discontinued intervention (n=20) due to: 
Feeling constipated (n=4) 
 Increased gas formation (n=1) 
Increased need to urinate (n=1) 
Worsening of Alzheimer symptoms (n=1)  
No reason given (n=12) 
Lost to follow-up (n=4)   
Discontinued intervention with no reason given (n=4) 
12 week follow-up 
Lost to follow-up (n=2)   
Discontinued intervention with no reason given (n=2) 
Completed the entire intervention (n=125) 
Declined participation before randomization (n=13) 
Completed the entire intervention (n=124) 
Fig. 1 Participant flow and adverse events
Östlund-Lagerström et al. Nutrition Journal  (2016) 15:80 Page 4 of 10
between the treatment groups were detected. As a final
step a Student’s t-test or Mann Whitney U-test was per-
formed to analyze the mean and median score, respect-
ively, between the two study arms for the secondary
questionnaires (e.g. HADS, PSS, EQ-5D-5L). The two
study arms were compared at week 8 and 12 after subtrac-
tion of the baseline score.
All analysis was performed blinded. 28 individual
questionnaires sheets (HADS: 11, PSS: 17, EuroQol: 0)
had to be excluded from the analysis due to missing
values in proportions that did not allow for imputation.
All data were stored in a common database and statistically
analyzed using r version 3.0 (Auckland, New Zeeland).
A p value < 0.05 was considered to be statistically sig-
nificant. All reported p-values are descriptive, without
multiplicity correction.
Results
Participant flow and baseline characteristics
Overall 290 older adults were randomized (93 % of 307
eligible study participants; 140 probiotic, 146 placebo
treatment, respectively) (Fig. 1). Retention to primary
outcome was 85 % (249 analyzed; 125 probiotic, 124 pla-
cebo treatment, respectively); 37 subjects were excluded
due to loss to follow up (Fig. 1). The baseline character-
istics did not differ significantly between the two treat-
ment groups, except that significantly more women and
a higher number of divorced study participants was in-
cluded in the placebo arm (Table 1).
Primary outcome
The ITT analysis as well as the per-protocol analysis did
not show any significant differences between the two treat-
ment groups (data not shown). The study population re-
ported a mean GSRS score of 1.9 ± 0.8, suggesting that a
large proportion of participants suffered from mild gut
problems. As no significant differences between the groups
could be observed, the trends are presented as mean ± SD
in the results section, to illustrate the subtle changes ob-
served throughout the study. Table 2 shows and compares
all primary and secondary outcomes (mean and median
values) at 8 and 12 weeks. Overall the two groups were
similar on almost all outcomes. The total mean score of
GSRS did not change markedly in either the placebo or
probiotic arm during the study (Fig. 2). Similarly, no sig-
nificant differences were observed in the separate domains
measured by GSRS (Table 2), except for the reflux domain
where a significant difference between groups occurred at
week 8; the reflux symptoms decreased in the placebo
group while increasing in the probiotic group (p = 0.02).
This trend, however, did not persist at week 12.
Secondary outcomes
Hospital and anxiety and depression scale
The two groups scored almost similar at week 8 and 12
and no significant differences could be observed in anxiety
or depression score (Table 2). Probiotic treatment did not
significantly affect depression score. Neither was probiotic
treatment or placebo found to decrease symptoms of
Table 2 Statistical findings shown as change from baseline at week 8 and 12
+8 week follow-up +12 week follow-up
Probiotic Placebo ST Probiotic Placebo ST
p-value p-value
Outcome parameter x ̅ Med x ̅ Med tT UT x ̅ Med x ̅ Med tT UT
GSRS −0.04 ± 0.6 0 (−0.3–0.3) −0.08 ± 0.6 −0.1 (−0.30.1) 0.63 0.18 −0.07 ± 0.6 0 (−0.4–0.2) −0.08 ± 0.6 −0.1 (−0.4–0.2) 0.91 0.42
Diarrhea −0.09 ± 0.7 0 (−0.7–0.3) −0.05 ± 1.0 0 (−0.3–0.3) 0.63 0.89 −0.12 ± 0.9 0 (−0.3–0.3) −0.05 ± 0.9 0 (−0.3–0) 0.61 0.52
Indigestion −0.14 ± 0.9 −0.3 (−0.6–0.3) −0.15 ± 0.8 0 (−0.5–0) 0.95 0.82 −0.14 ± 0.9 −0.1 (−0.5–0.3) −0.13 ± 0.7 0 (−0.5–0.3) 0.94 0.89
Constipation 0.02 ± 1.1 0 (−0.7–0.7) −0.03 ± 1.0 0 (−0.3–0.3) 0.76 0.46 −0.06 ± 1.1 0 (−0.7–0.3) −0.10 ± 1.1 0 (−0.3−0.3) 0.82 0.99
Abdom. pain −0.07 ± 0.6 0 (−0.3–0.2) −0.07 ± 0.7 0 (−0.3–0.3) 0.94 0.92 −0.08 ± 0.7 0 (−0.3–0.3) −0.09 ± 0.7 0 (−0.3–0.3) 0.95 0.86
Reflux 0.12 ± 0.7 0 (0–0) −0.13 ± 0.6 0 (0–0) 0.02a 0.02a −0.02 ± 0.7 0 (0–0) −0.09 ± 0.5 0 (0–0) 0.45 0.33
EQ-5D
Index 0 ± 0.1 0 (0–0) −0.01 ± 0.1 0 (−0.1–0) 0.35 0.23 0 ± 0.1 0 (0–0) 0 ± 0.1 0 (0–0) 0.87 0.79
VAS 1.89 ± 10.7 0 (−5–5) 0.60 ± 11.5 0 (−5–5) 0.44 0.76 2.88 ± 9.8 0 (−30–0) 3.47 ± 7.7 5 (0–10) 0.66 0.29
HADS −0.32 ± 3.5 0 (−2–1) −0.41 ± 2.9 0 (−2–1.3) 0.86 0.45 −0.18 ± 4.4 −0.5 (−2–1) 0.05 ± 5.2 0 (−2–2) 0.77 0.74
Depression −0.01 ± 2.1 0 (−1–1) −0.18 ± 1.9 0 (−1–0) 0.60 0.79 0.04 ± 2.2 0 (−1–1) −0.01 ± 2.8 0 (−1–1) 0.89 0.91
Anxiety −0.31 ± 2.1 0 (−1.3–1) −0.23 ± 1.9 0 (−1–1) 0.79 0.54 −0.22 ± 2.7 0 (−2–0.13) 0.06 ± 3.0 0 (−1–1) 0.55 0.42
PSS −0.41 ± 4.9 −1 (−3–2) −0.24 ± 5.4 0 (−3.8–3) 0.82 0.59 −1.55 ± 4.8 −1 (−5–2) −1.12 ± 4.4 −1 (−4–1.8) 0.57 0.58
x ̅ = Mean ± SD




asignificant at the 95 confidence level
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anxiety or depression in study participants experiencing
problems in these domains at baseline (data not shown).
Next, we investigated if study participants suffering from
gastrointestinal problems, (as judged by a score >2 on any
of the domains of GSRS) did experience any relief in anx-
iety or depression during the study. For subjects suffering
from indigestion symptoms, anxiety decreased by 0.73 ±
1.8 at week 8 in the probiotic arm compared to the pla-
cebo group where the symptoms increased by a score of
0.18 ± 1.5, p = 0.025. Subjects suffering from abdominal
pain showed a similar trend; symptoms of anxiety de-
creased with 0.75 ± 2.0 during probiotic treatment at week
8, compared to the placebo group where the symptoms
increased by a score of 0.4 ± 1.7 (p = 0.01). These effects,
however, did not persist at week 12. Thus, the observa-
tions were not consistent or relevant indicating that nei-
ther probiotic or placebo treatment was found to be able
to decrease symptoms of depression among participants
suffering from gastrointestinal symptoms.
Perceived stress scale
No significant differences in stress levels were observed
between the two study arms at week 8 and 12, respect-
ively (Table 2). An arbitrary cut off (≥ 15) was chosen in
order to investigate whether subjects suffering from
elevated stress at baseline changed their PSS scores over
the study period. This cut-off value was chosen based on
the frequency of stress problems among the study popu-
lation. A non-significant trend was found for the pro-
biotic treatment to decrease symptoms of stress with
(4.53 ± 4.2 compared to 2.2 ± 4.5 for placebo treatment,
respectively) over the study period, at week 12 (p = 0.20)
(Fig. 3). We further investigated whether a significant
change in stress level could be observed among study par-
ticipants experiencing gastrointestinal discomfort at base-
line. No such difference was observed (data not shown).
EQ-5D-5L
Similarly, as for the other outcomes, no significant dif-
ferences in subjective wellbeing were observed between
the probiotic and placebo arm (Table 2). The EQ-VAS
and 5Q-5D-index scores were almost similar in both
study arms at week 8 and 12, respectively. Both probiotic
and placebo treatment was associated with a significantly
increased subjective wellbeing at the week 12 (2.88 ± 9.8
and 3.47 ± 7.7 for probiotic and placebo treatment,
respectively). Neither did we identify any differences
in wellbeing between probiotic and placebo treatment
in subjects suffering from gastrointestinal symptoms
at baseline (data not shown).
Fig. 2 Changes in the primary outcome parameter over the study period. The figure shows change from baseline in GSRS total mean score in
the two treatment groups, throughout the intervention period. 178 subjects were included in the analysis, excluding participants taking PPI
and GMMS during the study. (Prob) indicates the probiotic group receiving treatment with L. reuteri (n = 86) and (PL) indicates the placebo
group (n = 92)
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Daily stool frequency
Probiotic treatment did not influence the stool frequency
in the outlined study. No significant differences were
found between the probiotic and placebo arm. Nor could
a difference bee seen within each group (data not shown).
Adherence and adverse events
Two hundred and forty nine study participants of the
290 that were enrolled finished the RCT.
Fifteen study participants in the probiotic arm and 22
participants in the placebo arm were lost to follow up
during week 8 and 12 (Fig. 1). Participants reporting the
reason for discontinuation as a result of illness were
equally distributed between the two treatment groups.
Discussion
In the present study, the effect of L reuteri DSM17938
was investigated on digestive health, wellbeing and psy-
chological distress in older adults in a randomized, pla-
cebo-controlled clinical trial. DSM17938 is a well-studied
probiotic strain and has been found to exert a positive
effect on constipation and diarrhea in adults and are
currently used as treatment of colic in infants in Sweden
[11, 15, 26, 27]. To our knowledge this is the first study in-
vestigating the effect of L reuteri in free-living older adults.
However, 12 weeks of treatment failed to show a differ-
ence in any of the outcome measures.
The study aimed to include a population of older adults
representing the general population. This is an important
group to investigate in a healthy aging perspective, as
these older adults in the near future will be in need of ele-
vated health care. Thus, it is within this group it is import-
ant to perform interventions that will promote health and
optimal functionality through out life.
The study population reported a mean GSRS score of
1.9 ± 0.8, suggesting that a large proportion of the study
participants did experience no or mild gut complaints,
results that are in line with our previous study [4]. Thus,
the study population was also comprised of persons
experiencing no gastrointestinal symptoms, without the
possibility to experience an improvement during the
intervention. It is therefore likely that the outlined study
would have gained from a larger sample size and/or a more
homogenous population focusing on one particular gut
problem. It is, however, important to consider that one
can expect rather modest treatment effects of probiotic
compounds. Thus, a population experiencing severe gut
problems might not be responsive to a probiotic effect.
The enrolled study population was found to experience a
better health status as judged by the low use of prescribed
medications according to reports from the Swedish
National Board of Health and Welfare [28]. It should
be noted that self-reporting of medication in this age-
group is problematic and often result in under-reporting
Fig. 3 Changes in psychological distress for subjects with elevated stress at baseline. The figure shows the 37 subjects with baseline PSS score
≥15, (Prob) indicates the probiotic group receiving treatment with L. reuteri (n = 17) and (PL) indicates the placebo group (n = 20). A modest
effect was found for the probiotic treatment to decrease symptoms of stress over the study period (4.53 ± 4.25 compared to 2.2 ± 4.5 for placebo
treatment, respectively (p = 0.20, statistical test: Mann-Whitney U-test))
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[29]. However, in this study data regarding medication
was collected in the home of the older adult with sup-
ported from the contact person.
Another aspect to consider in the RCT is the use of
GSRS as primary outcome measure. An additional more
fine tuned instrument such as the ROME III symptom
criteria, specifically developed for irritable bowel syn-
drome (IBS), might have increased the sensitivity and
allowed for detection of more subtle changes in gastro-
intestinal health throughout the study. In addition, it is a
risk that subjects suffering from IBS were not identified
and monitored throughout the study. However, it should
be noted that IBS patients responding positive to ROME
III symptom criteria commonly display more severe
symptoms as measured by GSRS modified for IBS [30].
Thus, it is likely that participants suffering from IBS
were included in the study, but, nevertheless, it is a limi-
tation that these subjects could not be specifically identi-
fied, as that would have been an important finding and
allowed for sub analyses.
Another reason for the negative outcome might be
a too low dose of L. reuteri. The dose was identical
to a previous clinical trial, reporting positive effects of
L. reuteri on constipation in adults [15]. However, L.
reuteri has been found to be more prevalent in sub-
jects over 66 years of age [31]. Thus, suggesting that
a higher dose might be needed in order to obtain a
positive effect in older adults.
In addition, an inadequate number of study partici-
pants were enrolled. Five hundred eleven older adults in
the region of Örebro responded to our advertisement
and notified their interest to participate in the study.
Three hundred and seven was still interested to partici-
pate after receiving an information letter regarding the
study. However, given the low number of participants
that were included in the final analysis (n = 249), add-
itional recruitment strategies should have been applied.
Thus, the study was underpowered. In addition, we
made the decision to exclude 71 subjects from the final
analysis as PPI and GMMS was found to affect and
interfere with the primary outcome parameter.
Use of PPI have been found to be associated with en-
teric Clostridium difficile infection (CDI) [32]. CDI is
commonly associated with diarrhea and long-term use
of antibiotics [33]. Thus, PPIs have the potential to affect
the composition of the gut microbiota and stool fre-
quency. In the current study antibiotic use the last six
months prior study start was an exclusion criterion. It is
therefore likely that no subject suffered from Clostrid-
ium difficile associated diarrhea. Nevertheless, given the
potential of PPI to affect the gastrointestinal tract use of
PPI should have been an exclusion criterion, particularly
as we were not able to recruit a sample size that allowed
for sub analysis.
GMMS is frequently used in the treatment of consti-
pation and diarrhea among older adults, regulating the
intestinal motility and stool frequency. Clearly, it would
have been a benefit for the study to set use of GMMS as
an exclusion criterion. However, in a pilot study it was
observed that older adults declined participation when
asked not to take GMMS during a month. Hence, we
decided to analyze the effect of GMMS intake in subse-
quent sub analysis after study finish.
In addition, 33 participants had to be excluded due to
missing or incomplete CRF. It is possible that data from
these participants would have an impact on the results.
However, we would still not reach the minimal required
sample size (n = 150) per arm. In addition, 28 question-
naires (HADS: 11; PSS: 17), had to be excluded from the
analysis due to missing values. For both PSS and
HADS no more than one item can be missed in order
for the questionnaire to be included in the analysis.
Given that 249 participants were included in the final
analysis the excluded questionnaires represent a modest
proportion and complete data sets would probably not
affect the outcome for the secondary parameters radically.
It is interesting to note that no items were missed when
the study participants filled out GSRS, the primary out-
come measure. Further, emphasizing that this instrument
is easy and works well in an older population. All partici-
pants did fulfill the inclusion criteria and were mentally fit
to complete the questionnaires. Only eight participants
scored below 26 on the Mini mental state exam (MMSE),
indicating mild cognitive impairment (data not shown).
However, mild cognitive impairment rarely causes changes
severe enough to interfere with daily life or independent
function and probably did not affect their ability to
complete the questionnaires.
Even though the trial had a negative outcome on the
primary parameter we did observe a modest effect of
probiotic treatment on stress level at week 8 and 12.
Similarly, we found that subjects suffering from indiges-
tion and abdominal pain, respectively, showed a signifi-
cant decrease of anxiety at week 8 after probiotic
treatment, but not at week 12. Similar findings have pre-
viously been reported and probiotic treatment has been
found to have an influence on anxiety, as measured by
HADS [34]. It should, however, be noted that our results
are based on self-reported data and thus, rely on the re-
spondents’ honesty, accurate understanding and inter-
pretation on the questions asked. Furthermore, it is
important to point out that the findings presented here
have not been corrected for multiple comparisons, thus
the p-values shown are only descriptive and should be
interpreted with caution.
In addition, the study product used in the study
also contained galactooligosaccharide a well-known pre-
biotic fiber, known to have a positive impact on the gut
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microbiota [35]. Thus, we cannot exclude that the modest
effects observed in the trial is due to a synbiotic effect.
Despite the negative outcome, the results outlined in
the present study highlights important issues that needs
to be taken into consideration when designing clinical
trials in older adults, particularly the high drop out rate
in this part of the population is essential to reflect upon
before starting the recruitment process.
In addition, it is evident that promoting gut health is
important in order to increase the over all health status
among older adults. Further studies will have to thoroughly
investigate the gut-brain axis and how this signaling path-
way changes with age. It will particularly be important to
investigate the relationship between common gut prob-
lems, such as constipation and diarrhea, and the compos-
ition of the gut microbiota in older adults. This will gain
insight on how aging affects gastrointestinal function and
will be essential knowledge to build on when designing
new RCTs to elucidate the effect of pro- and prebiotic
compounds in older adults.
Conclusion
The RCT failed to show any improvement in digestive
health after daily intake of a supplement containing the
probiotic strain L. reuteri during a three-month period.
Neither was any significant improvement in wellbeing,
stress or anxiety observed. Even though the trial had a
negative outcome, the study highlights important issues
that need to be taken into consideration when designing
clinical trials in older adults. Furthermore, it is evident
that promoting gut health may impact the over all health
status, including mental health, among older adults.
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